

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA**

BIOGEN INTERNATIONAL GMBH and
BIOGEN MA INC.,

Plaintiffs,

v.

MYLAN PHARMACEUTICALS INC.

Defendant.

C.A. No. 1:17-cv-116-IMK

NOTICE PURSUANT TO 35 U.S.C. § 282

Pursuant to 35 U.S.C. § 282, Defendant Mylan Pharmaceuticals Inc. (hereinafter “Mylan,” or “Defendant”), hereby identifies the following materials that may be relied upon to invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399,514 (“the ’514 patent”) (collectively the “patents-in-suit”) and/or show the state of the art relative to the asserted patents.

Mylan already provided notice to Plaintiffs Biogen International GmbH and Biogen MA Inc. (collectively “Biogen” or “Plaintiffs”) of the identity of certain publications, patents, and persons within the ambit of 35 U.S.C. § 282, through the pleadings and correspondence in this case, including but not limited to, invalidity contentions, expert witness reports, testimony, Defendant’s responses to interrogatories, and requests for production, Defendant’s disclosures under Rule 26, and/or the materials disclosed in either Defendant’s trial exhibit list or the joint trial exhibit list. Defendant expressly incorporates herein by reference all of the publications, patents, and specifications of persons within the ambit of 35 U.S.C. § 282 previously cited in these pleadings, testimony, correspondence, and other materials.

Defendant may also rely on the patentees/authors of the patents and publications listed below as being prior inventors or as having prior knowledge of or as having previously used or offered for sale the inventions of the patents-in-suit.

Pursuant to the statutory provisions of 35 U.S.C. § 282, Defendant further refers to the list of identified publications, materials, and persons below. The inclusion of the references listed below in this notice should not be construed as a representation that Defendant will use every one of the references in its presentation of evidence at trial. Nor should it be understood or taken as implied that reliance upon all of these materials is necessary to Defendant's defenses. Additionally, Defendant reserves the right to amend and/or supplement this notice to add items to this statement that were inadvertently omitted.

A. Patents and File Histories

Patent/Patent Publication No.	Date of Issue/ Publication Date	Country of Origin	Named Inventor(s)
3,175,521	3/30/65	United States	E.B. Hershberg
4,233,161	11/11/80	United States	Haruhito Sato; Hiroshi Ichikawa; Hiroshi Hayashi; Konomu Kurisaki
4,572,833	2/25/86	United States	Arne M. Pedersen; Jens R. Jensen
4,828,843	5/9/89	United States	Claus H. Pich; Thomas Moest
4,851,439	7/25/89	United States	Peter P. Speiser; Rajendra K. Joshi
4,959,389	9/25/90	United States	Peter P. Speiser; Rajendra K. Joshi
5,009,897	4/23/91	United States	Dale R. Brinker; Thomas L. Reiland
5,167,964	12/1/92	United States	Nouman Muhammad; Michael Harris; Jay Weiss; Russell U. Nesbitt
5,428,040	6/27/95	United States	Ronald L. Magolda; William J. Pitts; Irina C. Jacobson; Carl H. Behrens; Michael J. Orwat; Douglas G. Batt

Patent/Patent Publication No.	Date of Issue/ Publication Date	Country of Origin	Named Inventor(s)
5,681,588	10/28/97	United States	Karl Kolter; Helmut Fricke; Volker Buehler; Herbert Mueller-Peltzer
6,436,992	8/20/02	United States	Rajendra Kumar Joshi; Hans Peter Strelbel
6,509,376	1/21/03	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
7,320,999	1/22/08	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
7,803,840	9/28/10	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
8,759,393	6/24/14	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
EP 0 211 946	5/23/90	Europe	Charles Hsiao; Chi-Tze Ku Chou
EP 0 574 894	9/18/96	Europe	Tibor Sipos
U.S. Patent App. Pub. No. 2009/0304790	12/10/09	United States	Henrik Nilsson; Florian Schoenharting; Bernd W. Mueller; Joseph R. Robinson; Bonna Robinson
U.S. Patent App. Pub. No. US 2003/0013761 A1	1/16/03	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
U.S. Patent App. Pub. No. US 2005/0148664 A1	7/7/05	United States	Rajendra K Joshi; Hans-Peter Strelbel
U.S. Patent Pub. No. US 2003/0018072 A1	1/23/03	United States	Rajendra Kumar Joshi; Hans-Peter Strelbel
WO 2005/023241 A1	3/17/05	PCT	Rajendra Kumar Joshi; Hans-Peter Strelbel; Christian Zaugg; Michael Tamm
WO 2006/0037342 A2	4/13/06	PCT	Henrik Nilsson; Florian Schönharting; Bernad W. Müller; Joseph R. Robinson
WO 2007/042034	4/19/07	PCT	Henrik Nilsson; Bernd W. Muller
WO 92/04013	3/19/92	PCT	Giovanni Bongiovanni; Massimo Maria Calanchi; Marco Giuseppe Raffaele Marconi

B. Publications

Publication	Production No. (If Applicable)
A. Miller et al., <i>Treatment of Multiple Sclerosis with Copolymer-1 (Copaxone®): Implicating Mechanisms of Th1 to Th2/Th3 Immune-Deviation</i> , 92 J. NEUROIMMUN. 113 (1998)	MYL-DMF-00064894 - MYL-DMF-00064902
Alarie, <i>Sensory Irritation by Ariborne Chemicals</i> , 2 CRC CRITICAL REVIEWS IN TECH 299 (1973)	MYL-DMF-00059267 - MYL-DMF-000693332
Alphin et al., <i>Irritative Properties of Two Clinical Potassium Chloride Formulations on Duodenal Mucosa of the Cat and Esophageal Mucosa of the Opossum</i> , 29(6) DIGESTIVE DISEASES & SCIENCES 508 (1984)	
Altmeyer et al., <i>Antipsoriatic Effect of Fumaric Acid Derivatives: Results of a Multicenter Double-Blind Study in 100 Patients</i> , 30 J. AM. ACAD. DERMATOL. 977 (1994)	MYL-DMF-00060099 - MYL-DMF-00060103
Asadullah et al., <i>Novel Immunotherapies for Psoriasis</i> , 23(1) TRENDS IN IMMUNOLOGY 47 (2002)	
B. Crucian et al., <i>Detection of Altered T Helper 1 and T Helper 2 Cytokine Production by Peripheral Blood Mononuclear Cells in Patients with Multiple Sclerosis Utilizing Intracellular Cytokine Detection by Flow Cytometry and Surface Marker Analysis</i> , 3(4) CLIN. & DIG. LAB. IMMUN. 411 (1996)	MYL-DMF-00061133 - MYL-DMF-00061138
Barten et al., <i>Vascular Cell Adhesion Molecule-1 Modulation by Tumor Necrosis Factor in Experimental Allergic Encephalomyelitis</i> , 51 J. NEUROIMMUNOLOGY 123 (1994)	MYL-DMF-00059333 - MYL-DMF-00059343
Bechgaard et al., <i>Controlled-Release Multiple-Units and Single-Unit Doses: A Literature Review</i> , 4(1) DRUG DEV. & INDUS. PHARM. 53 (1978)	MYL-DMF-00059344 - MYL-DMF-00059358
Begleiter et al., <i>Dietary Induction of NQO1 Increases the Antitumour Activity of Mitomycin C in Human Colon Tumours in vivo</i> , 91 BR. J. CANCER 1624 (2004)	
Benvenuto et al., <i>Tumor Necrosis Factor-Alpha Synthesis by Cerebrospinal-Fluid Derived T Cell Clones from Patients with Multiple Sclerosis</i> , 84 CLIN. EXP. IMMUNOL. 97 (1991)	MYL-DMF-00059359 - MYL-DMF-00059364
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative - Fumapharm/Biogen Idec, 6(4) DRUGS R.D. 229 (2005)	
Biogen News Release, <i>Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis</i> (Jan. 9, 2006)	MYL-DMF-00059860 - MYL-DMF-00059861
Biogen News Release, <i>BG-12 Psoriasis Study Meets Primary Endpoint; Oral Compound Also Being Studied for MS in Phase II Trial</i> (Apr. 7, 2005)	MYL-DMF-00060086 - MYL-DMF-00060088

Publication	Production No. (If Applicable)
Biogen News Release, <i>Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12 Led to Statistically Significant Reductions in MRI Measures</i> (May 30, 2006)	MYL-DMF-00060034 - MYL-DMF-00060036; BiogenF70015995 - BiogenF70115996
Biogen News Release, <i>Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 being Studied for Multiple Sclerosis</i> (May 31, 2006), available at https://www.businesswire.com/news/home/20060531005276/en/Biogen-Idec-Acquire-Fumapharm-AG-Consolidates-Ownership	
Bodansky et al., <i>The Toxicity and Laxative Action of Sodium Fumarate</i> , 31 J. AM. PHAR. ASSOC. 1 (1942)	MYL-DMF-00059398 - MYL-DMF-00059405
Brune et al., <i>Detection of Altered Intracellular TH₁ and TH₂-Type Cytokine Production of Peripheral Blood Mononuclear Cells (PBMCa) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Undergoing an Oral Fumaric-Acid Ester Therapy</i> , 4(4) MULTIPLE SCLEROSIS: CLINICAL & LABORATORY RESEARCH P3038 (1998) (ECTRIMS 98: 14th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, September 9-12, 1998, Stockholm, Sweden)	MYL-DMF-00060114 - MYL-DMF-00060120
Brune et al., <i>Oral Fumarate Therapy Alters Cytokine Production in Patients with Relapsing-Remitting Multiple Sclerosis</i> , 10(suppl. 2) MULTIPLE SCLEROSIS CLINICAL & LAB. RES. S259, Abstract P643 (2004)	MYL-DMF-00060023 - MYL-DMF-00060027
Brune et al., <i>Oral Fumaric-Acid Ester Therapy (FAE) Influence T-Helper Cell Apoptosis in Peripheral Blood Lymphocytes (PBLS) and Soluble Intercellular Adhesion Molecule-I (SICAM-1) in Serum of Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)</i> , 246(Suppl. 1) J. NEUROL. 1/61, P272 (1999) (Ninth Meeting of the European Neurological Society, June 5-9, 1999, Milan, Italy)	MYL-DMF-00060194 - MYL-DMF-00060198
C. Bolton, <i>Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment</i> , 1 MULTIPLE SCLEROSIS 143 (1995)	MYL-DMF-00061115 - MYL-DMF-00061121
C. Fryhle et al., <i>Isomerization of Dimethyl Maleate to Dimethyl Fumarate: An Undergraduate Experiment Illustrating Amine-Catalyzed Alkene Isomerization, Stereochemical Principles, Sublimation, and Product Identification by Spectroscopic Methods</i> , 68(12) J. CHEM. EDUC. 1050 (1991)	MYL-DMF-00064575 - MYL-DMF-00064578
CRC HANDBOOK OF CHEMISTRY & PHYSICS (Robert C. Weast et al. eds., 66th ed. 1985)	
D.L. Munday et al., <i>Controlled Release Delivery: Effect of Coating Composition on Release Characteristics of Mini-Tablets</i> , 52 INT'L J. PHARM. 109 (1989)	MYL-DMF-00064903 - MYL-DMF-00064908

Publication	Production No. (If Applicable)
Davis et al., <i>Transit of Pharmaceutical Dosage Forms Through the Small Intestine</i> , 27 GUT 886 (1986)	
de Haan et al., <i>The Risk of Sensibilization and Contact Urticaria upon Topical Application of Fumaric Acid Derivatives</i> , 188 DERMATOLOGY 126 (1994)	MYL-DMF-00060500 - MYL-DMF-00060504
de Jong et al., <i>Selective Stimulation of T Helper 2 Cytokine Responses by the Anti-Psoriasis Agent Monoethylfumarate</i> , 26 EUR. J. IMMUNOL. 2067 (1996)	MYL-DMF-00060065 - MYL-DMF-00060072
de Klerk et al., <i>Patient Compliance in Rheumatoid Arthritis, Polymyalgia Rheumatica, and Gout</i> , 30 J. RHEUMATOLOGY 44 (2003)	MYL-DMF-00060277 - MYL-DMF-00060288
Del Prete, <i>The Concept of Type-1 and Type-2 Helper T Cells and Their Cytokines in Humans</i> , 16 INT REV IMMUNOL. 427 (1998)	MYL-DMF-00059424 - MYL-DMF-00059453
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis, CLINICALTRIALS.GOV ARCHIVE (Sept. 14, 2005)	MYL-DMF-00059966 - MYL-DMF-00059977
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis, CLINICALTRIALS.GOV ARCHIVE (Sept. 14, 2005)	MYL-DMF-00059978 - MYL-DMF-00059984
Eisen et al., <i>The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance</i> , 150 ARCH. INTERN. MED. 1881 (1990)	MYL-DMF-00060295 - MYL-DMF-00060298
European Medicines Agency, <i>Assessment Report, Tecfidera</i> (Nov. 26, 2013)	MYL-DMF-00064383 - MYL-DMF-00064508
FDA Guidance for Industry, <i>Non-Inferiority Clinical Trials to Establish Effectiveness</i> (Nov. 2016)	MYL-DMF-00064519 - MYL-DMF-00064574
Flemming et al., <i>Requirements for the Production of Microtablets: Suitability of Direct-Compression Excipients Estimated from Powder Characteristics and Flow Rates</i> , 21(19) DRUG DEV. & INDUS. PHARM. 2239 (1995)	MYL-DMF-00060469 - MYL-DMF-00060482
Fox et al., <i>Dimethyl Fumarate to Treat Multiple Sclerosis</i> , in MULTIPLE SCLEROSIS THERAPEUTICS (Jeffrey A. Cohen et al. eds., 4th ed. 2011)	
Fox et al., <i>Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis</i> , 367 NEW ENG. J. MED. 1087 and supplementary appendix (2012)	BiogenF70003369 - BiogenF70003533
Frohman et al., <i>Multiple Sclerosis – the Plaque and its Pathogenesis</i> , 354 NEW ENG. J. MED. 942 (2006)	MYL-DMF-00060144 - MYL-DMF-00060157
Fumaderm® Label	MYL-DMF-00060056 - MYL-DMF-00060064

Publication	Production No. (If Applicable)
<i>Gan et al., In Vitro Dissolution Profiles of Enteric-Coated Microsphere/Microtablet Pancreatin Preparations at Different pH Values, 10 ALIMENT PHARMACOL THER 771 (1996)</i>	MYL-DMF-00060483 - MYL-DMF-00060487
<i>Ghoreschi & Rocken, Immune Deviation Strategies in the Therapy of Psoriasis, 3 CURRENT DRUG TARGETS 194 (2004)</i>	
<i>Gold et al., Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis, 367 NEW ENG. J. MED. 1098 and supplementary appendix (2012)</i>	BiogenF70003534 - BiogenF70003811
<i>H.C. Ansel et al., PHARMACEUTICAL DOSAGE FORMS & DRUG DELIVERY SYSTEMS (6th ed. 1995)</i>	BiogenF70020340 - BiogenF70020377
<i>H.M. Hung et al., Testing for the Existence of a Desirable Dose Combination, 49 BIOMETRICS 85 (1993)</i>	MYL-DMF-00064859 - MYL-DMF-00064869
<i>HANDBOOK OF PHARMACEUTICAL EXCIPIENTS (Ainley Wade & Paul J. Weller eds., 2d ed. 1994)</i>	MYL-DMF-00064827 - MYL-DMF-00064832
<i>Immunomodulation through Fumaderm, Charite - Berlin Dermatological Clinic Symposium (Nov. 1-3, 1996)</i>	MYL-DMF-00059365 - MYL-DMF-00059397
<i>International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Dose-Response Information to Support Drug Registration E4, Current Step 4 version, dated 10 March 1994</i>	MYL-DMF-00059985 - MYL-DMF-00059998
<i>J. Cohen, Theophylline, 4 ANALYTICAL PROFILES OF DRUG SUBSTANCES 466 (1975)</i>	
<i>J. Cohen et al., Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS, 68 NEUROLOGY 939 (2007)</i>	
<i>J. Laman, Balancing the Th1/Th2 Concept in Multiple Sclerosis, 19(11) IMMUNOLOGY TODAY 489 (1998)</i>	MYL-DMF-00064873 - MYL-DMF-00064874
<i>J. Phillips et al., BG-12 in Multiple Sclerosis, 33 SEMIN. NEUROL. 56 (2013)</i>	MYL-DMF-00064909 - MYL-DMF-00064918; BiogenF10152449 - BiogenF10152458
<i>J.R. Crout, Fixed Combination Prescription Drugs: FDA Policy, 14 J. CLIN. PHARM. 249 (1974)</i>	MYL-DMF-00061127 - MYL-DMF-00061132
<i>Kappos et al., A Randomised, Placebo-Controlled Phase II Trial of a Novel Oral Single-Agent Fumarate Therapy, BG00012, in Patients with Relapsing-Remitting Multiple Sclerosis, 252 [Suppl 2] J. NEUROL. II/148, P574 (2005)</i>	MYL-DMF-00060032 - MYL-DMF-00060033
<i>Kappos et al., A Randomized, Placebo-Controlled Phase 2 Trial of Novel Oral Fumarate, BG00012, in Patients with Relapsing-Remitting Multiple Sclerosis, 15th Meeting of the European Neurological Society (June 18-22, 2005), and Declaration of Gilmore O'Neill, M.D.</i>	MYL-DMF-00060126 - MYL-DMF-00060131

Publication	Production No. (If Applicable)
Kappos et al., <i>Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study</i> , 372 LANCET 1463 (2008)	MYL-DMF-00064509 - MYL-DMF-00064518; BiogenF10143523 - BiogenF10143532
Kappos et al., <i>Efficacy of a Novel Oral Single-Agent Fumarate, BG00012, in Patients with Relapsing-Remitting Multiple Sclerosis: Results of a Phase 2 Study</i> , 253 (Suppl. 2) J. NEUROL. O108 (2006)	MYL-DMF-00059867 - MYL-DMF-00059893
Kappos et al., <i>Efficacy of a Novel Oral Single-Agent Fumarate, BG00012, in Patients with Relapsing-Remitting Multiple Sclerosis: Results of a Phase II Study</i> , 16th Meeting of the European Neurological Society (May 30, 2006) attached as Exhibit C to the Declaration of Katherine T. Dawson in Biogen U.S. Patent App. No. 12/526,296 and marked as Ex. 1018 in <i>Biogen MA Inc. v. Forward Pharma A/S</i> , Interference No. 106,023	MYL-DMF-00060199 - MYL-DMF00060227
Kolbach et al., <i>Fumaric Acid Therapy in Psoriasis: Results and Side Effects of 2 Years of Treatment</i> , 27(5) J. AM. ACAD. DERMATOL. 769 (1992)	MYL-DMF-00060505 - MYL-DMF-00060507
A. Langner et al., <i>Results of a Phase 2 Dose-Ranging and Safety Extension Study of a Novel Oral Fumarate, BG-12, in Patients with Severe Psoriasis</i> , 52 J. AM. ACAD. DERMATOL. P193, P2787 (2005)	
L. Friedman et al., FUNDAMENTALS OF CLINICAL TRIALS (5th ed. 2015)	MYL-DMF-00064579 - MYL-DMF-00064826
Lennartz et al., <i>Minitabletting: Improving the Compactability of Paracetamol Powder Mixtures</i> , 173 INT'L J. PHARM. 75 (1998)	MYL-DMF-00060525 - MYL-DMF-00060535
Leon Shargel et al., APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS, 575-611 (5th ed. 2005)	MYL-DMF-00060228 - MYL-DMF-00060276
Lublin, <i>History of Modern Multiple Sclerosis Therapy</i> , 252 J. NEUROL. III/3 (2005)	MYL-DMF-00060536 - MYL-DMF-00060542
Marilyn Much, <i>Biogen's Multiple Sclerosis Pill May Turn into Blockbuster Drug</i> , 30(98) IBD, Aug. 26, 2013	BiogenF10159750 - BiogenF10159754
McMahon et al., <i>Upper Gastrointestinal Lesions After Potassium Chloride Supplements: A Controlled Clinical Trial</i> , THE LANCET (1982)	
Meier et al., <i>Monitoring Treatment Efficacy with Magnetic Resonance Imaging (MRI) in an Open Phase II Study with Fumaric-Acid Esters (Fumaderm®) in Patients with Relapsing-Remitting MS (RRMS)</i> , 4(4) MULTIPLE SCLEROSIS: CLINICAL & LABORATORY RESEARCH P3037 (1998) (ECTRIMS 98: 14th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, September 9-12, 1998, Stockholm, Sweden)	MYL-DMF-00060187 - MYL-DMF-00060193
Miller, <i>The Importance of Early Diagnosis of Multiple Sclerosis</i> , 10(3) J. MANAG. CARE PHARM. S4 (2004)	MYL-DMF-00060158 - MYL-DMF-00060171

Publication	Production No. (If Applicable)
Mrowietz et al., <i>Dimethylfumarate for Psoriasis: More than a Dietary Curiosity</i> , 11(1) TRENDS MOL. MED. 43 (2005)	MYL-DMF-00060050 - MYL-DMF-00060055
Mrowietz et al., <i>Treatment of Psoriasis with Fumaric Acid Esters: Results of a Prospective Multicentre Study</i> , 138(3) BR. J. DERMATOL. 456 (1998)	MYL-DMF-00061069 - MYL-DMF-00061075
Mrowietz et al., <i>Treatment of Severe Psoriasis with Fumaric Acid Esters: Scientific Background and Guidelines for Therapeutic use</i> , 141 BR. J. DERM. 424 (1999)	
MS Prevalence, NATIONALMSSCOIETY.ORG, https://www.nationalmsscoiety.org/About-the-Society/MS-Prevalence (last visited July 9, 2018)	MYL-DMF-00060172 - MYL-DMF-00060173
MULTIPARTICULATE DRUG DELIVERY (Ali R. Rajabi-Siahboomi ed., 2017)	MYL-DMF-00060543 - MYL-DMF-00060944
MULTIPARTICULATE ORAL DRUG DELIVERY (Issac Ghebre-Sellassie ed., 1994)	MYL-DMF-00060488 - MYL-DMF-00060499
Munday, <i>A Comparison of the Dissolution Characteristics of Theophylline from Film Coated Granules and Mini-Tablets</i> , 20(15) DRUG DEV. & INDUS. PHARM. 2369 (1994)	MYL-DMF-00060945 - MYL-DMF-00060955
N. Holford et al., <i>Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models</i> , 6 CLIN. PHARMACOKINETICS 429 (1981)	MYL-DMF-00064833 - MYL-DMF-00064858
Navikas & Link, <i>Review: Cytokines and the Pathogenesis of Multiple Sclerosis</i> , 45 J. NEUROSCI. RES. 322 (1996)	MYL-DMF-00060956 - MYL-DMF-00060967
Nibbering et al., <i>Effects of Monoethylfumarate on Human Granulocytes</i> , 101 J. INVEST. DERMATOL 37 (1993)	MYL-DMF-00060073 - MYL-DMF-00060078
Nieboer et al., <i>Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester</i> , 181 DERMATOLOGICA 33 (1990)	MYL-DMF-00060037 - MYL-DMF-00060042
Nieboer et al., <i>Systemic Therapy with Fumaric Acid Derivates: New Possibilities in the Treatment of Psoriasis</i> , 20 J. AM. ACAD. DERM. 601 (1989)	MYL-DMF-00060104 - MYL-DMF-00060113
Nugteren-Huying et al., <i>Fumaric Acid Therapy for Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Study</i> , 22 J. AM. ACAD. DERMATOL. 311 (1990)	MYL-DMF-00060092 - MYL-DMF-00060096
Ockenfels et al., <i>The Antipsoriatic Agent Dimethylfumarate Immunomodulates T-Cell Cytokine Secretion and Inhibits Cytokines of the Psoriatic Cytokine Network</i> , 139 BRIT. J. DERMATOL. 390 (1998)	MYL-DMF-00061061 - MYL-DMF-00061068
Olsson, <i>Cytokine-Producing Cells in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis</i> , 45(Suppl. 6) NEUROLOGY S11 (1995)	MYL-DMF-00060968 - MYL-DMF-00060973
O'Neill, <i>BG00012 in RRMS: Update from Phase 2 Study</i> , National Faculty Meeting, Bonita Springs (Jan. 27-29, 2006)	BiogenF10151012 - BiogenF10151025

Publication	Production No. (If Applicable)
Ormerod et al, <i>Fumaric Acid Esters, Their Place in the Treatment of Psoriasis</i> , 150 Br. J. DERM. 630 (2004)	MYL-DMF-00060089 - MYL-DMF-00060091
Paes et al., <i>Impact of Dosage Frequency on Patient Compliance</i> , 20(10) DIABETES CARE 1512 (1997)	MYL-DMF-00060289 - MYL-DMF-00060294
Panitch et al., <i>Clinical Trials of Interferons in Multiple Sclerosis: What have we learned?</i> , 46 J. NEUROIMMUNOLOGY 155 (1993)	MYL-DMF-00060974 - MYL-DMF-00060983
Pharma Times News Release, <i>Biogen Idec says Oral MS Drug Clears Ph II Study</i> (Jan. 10, 2006)	
PHARMACEUTICAL DOSAGE FORMS: TABLETS, VOL. 1 (H.A. Lieberman et al. eds. 1980)	BiogenF70020490 - BiogenF70020494
PHARMACEUTICAL DOSAGE FORMS: TABLETS, VOL. 1 (H.A. Lieberman et al. eds., 2d ed. 1989)	MYL-DMF-00064875 - MYL-DMF-00064889
PHYSICIANS' DESK REFERENCE (52d ed. 1998)	MYL-DMF-00061110 - MYL-DMF-00061114
R. Martin et al., <i>T Helper Cell differentiation in Multiple Sclerosis and Autoimmunity</i> , 19(11) IMMUNOLOGY TODAY 495 (1998)	MYL-DMF-00064890 - MYL-DMF-00064893
Ransohoff, <i>Multiple Sclerosis - A Quiet Revolution</i> , 11(3) NAT REV NEUROL 134 (2015)	MYL-DMF-00060984 - MYL-DMF-00060993
Reingold, <i>Advances in the Understanding and Treatment of Multiple Sclerosis</i> , 44 J. NEUROIMM. 221 (1993)	MYL-DMF-00060994 - MYL-DMF-00060997
REMINGTON: THE SCIENCE & PRACTICE OF PHARMACY (Alfonso R. Gennaro ed., 19th ed. 1995)	MYL-DMF-00064919 - MYL-DMF-00064927
REMINGTON'S PHARMACEUTICAL SCIENCES (A.R. Gennaro et al. eds., 18th ed. 1990)	
REMINGTON'S PHARMACEUTICAL SCIENCES (A.R. Gennaro et al. eds., 19th ed. 1995)	MYL-DMF-00060998 - MYL-DMF-00061003
Reuters News Release, <i>Biogen Idec Inc. and Fumapharm AG Announce Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis</i> (Jan. 9, 2006)	
Rich et al., <i>Stepped-Care Approach to Treating MS: A Managed Care Treatment Algorithm</i> , 10(3) J. MANAG. CARE PHARM. S26 (2004)	MYL-DMF-00060174 - MYL-DMF-00060186
Romagnani, <i>Lymphokine Production by Human T Cells in Disease States</i> , 12 ANNU. REV. IMMUNOL. 227 (1994)	MYL-DMF-00061004 - MYL-DMF-00061034
Schimrigk et al., <i>A Prospective, Open-Label, Phase II Study of Oral Fumarate Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis</i> , 10(suppl. 2) MULTIPLE SCLEROSIS CLINICAL & LAB. RES. S258, Abstract P642 (2004)	MYL-DMF-00059862 - MYL-DMF-00059866
Schimrigk et al., <i>A Prospective, Open-Label, Phase II Study of Oral Fumarate Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis</i> (2004), available at http://web.archive.org/web/20041021033354/http://www.fumapharm.ch:80/pdf-BG-12_Schimrigk_Poster_Final.pdf	MYL-DMF-00060013 - MYL-DMF-00060022

Publication	Production No. (If Applicable)
Schimrigk et al., <i>An Open-Label, Prospective Study of Oral Fumaric Acid Therapy for the Treatment Relapsing-Remitting Multiple Sclerosis (RRMS)</i> , 64(6) (Suppl. 1) NEUROLOGY A392, S46.003 (2005)	MYL-DMF-00060028 - MYL-DMF-00060031
Schimrigk et al., <i>Oral Fumaric Acid Ester (FAE) in Relapsing-Remitting Multiple Sclerosis (RRMS). A Short Term, Open, Clinical, Immunological and Magnetic Resonance Imaging (MRI) Controlled Phase II Trial</i> , 246(Suppl. 1) J. NEUROL. I/36, 144 (1999) (Ninth Meeting of the European Neurological Society, June 5-9, 1999, Milan, Italy)	MYL-DMF-00060121 - MYL-DMF-00060125
Schimrigk et al., <i>Oral Fumaric Acid Esters for the Treatment of Active Multiple Sclerosis: An Open-Label, Baseline-Controlled Pilot Study</i> , 13 EUR. J. NEUROL. 604 (2006)	MYL-DMF-00060043 - MYL-DMF-00060049
Schlaak et al., <i>T Cells Involved in Psoriasis Vulgaris Belong to Th1 Subset</i> , 102 J. INVEST. DERMATOL. 145 (1994)	MYL-DMF-00061035 - MYL-DMF-00061039
Schmid et al., <i>Monomethylhydrogenfumarate Induces IL-10 Secretion of PBMCs From Psoriatic Patients</i> , 196 IMMUNOBIOLOGY 20 (Abstr.) (1996)	
Schmidt et al., <i>Reactivity of Dimethyl Fumarate and Methylhydrogen Fumarate Towards Glutathione and N-Acetyl-L-Cysteine-Preparation of S-Substituted Thiosuccinic Acid Esters</i> , 15 BIOORGANIC & MEDICINAL CHEMISTRY 333 (2007)	
Schmidt, R., <i>Dose-Finding Studies in Clinical Drug Development</i> , 34 EUR J. CLIN PHARMACOL 15 (1988)	
Sean Williams, <i>The Greatest Thing Since Sliced Bread has Arrived for MS Patients</i> , FOOL.COM (Mar. 28, 2013), https://www.fool.com/investing/general/2013/03/28/biogen-idec-tecfidera-approval-biib.aspx	BiogenF10159765 - BiogenF10159767
Sebok et al., <i>Antiproliferative and Cytotoxic Profiles of Antipsoriatic Fumaric Acid Derivates in Keratinocyte Cultures</i> , 270 EUR. J. PHARMACOL. 79 (1994)	
Shilling et al., <i>Fumaric Acid Esters are Effective in Chronic Experimental Autoimmune Encephalomyelitis and Suppress Macrophage Infiltration</i> , 145 CLINICAL & EXPERIMENTAL IMMUNOLOGY 101 (2006)	
Soderstrom et al., <i>Autoimmune T Cell Repertoire in Optic Neuritis and Multiple Sclerosis: T Cells Recognising Multiple Myelin Proteins are Accumulated in Cerebrospinal Fluid</i> , 57 J. NEUROLOGY, NEUROSURGERY, & PSYCHIATRY 544 (1994)	MYL-DMF-00061040 - MYL-DMF-00061047
Steffen et al., <i>Evidence for Involvement of ICAM-1 and VCAM-1 in Lymphocyte Interaction with Endothelium in Experimental Autoimmune Encephalomyelitis in the Central Nervous System in the SJL/J Mouse</i> , 145 AMERICAN J. OF PATHOLOGY 1 (1994)	MYL-DMF-00061048 - MYL-DMF-00061060

Publication	Production No. (If Applicable)
T. Koudriavtseva et al., <i>Gadolinium Enhanced MRI Predicts Clinical and MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis</i> , 62 J. NEURO., NEUROSURGERY, & PSYCH. 285 (1997)	MYL-DMF-00064870 - MYL-DMF-00064872
Trenktrig et al., <i>Enteric Coated Insulin Pellets: Development, Drug Release and In Vivo Evaluation</i> , 4 EUR. J. PHARM. SCIS. 323 (1996)	MYL-DMF-00061076 - MYL-DMF-00061082
UNITED STATES PHARMACOPEIA 1795-96 (USP 23 1995)	MYL-DMF-00061101 - MYL-DMF-00061104
United States Securities and Exchange Commission Form 10-K for Biogen Idec Inc., year ended Dec. 31, 2005	
Vandermeeren et al., <i>Dimethylfumarate is an Inhibitor of Cytokine-Induced E-Selectin, VCAM-1, and ICAM-1 Expression in Human Endothelial Cells</i> , 234 BIOCHEM. & BIOPHYS. RES. COMMUN'S 19 (1997)	MYL-DMF-00061105 - MYL-DMF-00061109
Vandermeeren et al., <i>Dimethylfumarate is an Inhibitor of Cytokine-Induced Nuclear Translocation of NF-κB1, but not RelA in Normal Human Dermal Fibroblast Cells</i> , 116 J. INVEST. DERMATOL. 124 (2001)	MYL-DMF-00064945 - MYL-DMF-00064951
Werdenberg, et al., <i>Presystemic Metabolism and Intestinal Absorption of Antipsoriatic Fumaric Acid Esters</i> , 24 BIOPHARM. DRUG DISPOS. 259 (2003), Published online in Wiley	
Wierinckx et al., <i>Detoxication Enzyme Inducers Modify Cytokine Production in Rat Mixed Glial Cells</i> , 166(1-2) J. NEUROIMMUNOL. 132 (2005)	MYL-DMF-00060132 - MYL-DMF-00060143
Y. Chen et al., <i>Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis</i> , 265 SCIENCE 1237 (1994)	MYL-DMF-00061122 - MYL-DMF-00061126

C. Persons Upon Whom Defendants May Rely as a Prior Inventor or as Having Prior Knowledge of or as Having Previously used or Offered for Sale the Invention of the Asserted Patents

All patentees, applicants, and authors of the patents and publications listed above.

Dated: January 3, 2020

Of Counsel:

Shannon M. Bloodworth
SBloodworth@perkinscoie.com
Brandon M. White
BMWhite@perkinscoie.com
Michael A. Chajon
MChajon@perkinscoie.com
700 Thirteenth Street, N.W., Suite 600
Washington, D.C. 20005-3960
Phone: 202.654.6200
Facsimile: (202) 654.6211

David L. Anstaett
DAnstaett@perkinscoie.com
Emily J. Greb
EGreb@perkinscoie.com
PERKINS COIE LLP
33 East Main Street, Suite 201
Madison, WI 53703
Phone: (608) 663-7460

Courtney M. Prochnow
CProchnow@perkinscoie.com
PERKINS COIE LLP
633 W. 5th Street, Suite 5850
Los Angeles, CA 90071
Phone: (310) 788-9900

By: /s/ William J. O'Brien

Gordon H. Copland
gordon.copland@steptoe-johnson.com
William J. O'Brien
william.obrien@steptoe-johnson.com
Adam S. Ennis
adam.ennis@steptoe-johnson.com
STEPTOE & JOHNSON PLLC
400 White Oaks Boulevard
Bridgeport, WV 26330
Phone: (304) 933-8000

Attorneys for Defendant
MYLAN PHARMACEUTICALS INC.

CERTIFICATE OF SERVICE

I hereby certify that on January 3, 2020, I filed the foregoing NOTICE PURSUANT TO 35 U.S.C. § 282 with the Clerk of the Court through the CM/ECF system, which will send notice of the filing to the following counsel of record:

Andrew E. Renison	James F. Companion
Andrew.renison@finnegan.com	jfc@schraderlaw.com
James B. Monroe	Sandra K. Law
James.monroe@finnegan.com	skl@schraderlaw.com
Li Feng	Frank X. Duff
li.feng@finnegan.com	fxd@schraderlaw.com
Sanya Sukduang	SCHRADER, BYRD & COMPANION, PLLC -
Sanya.sukduang@finnegan.com	WHEELING
Jeanette M. Roorda	The Maxwell Centre, Suite 500
Jeanette.roorda@finnegan.com	32-20th Street
Paul W. Browning	Wheeling, WV 26003
paul.browning@finnegan.com	
Lauren J. Dowty	
lauren.dowty@finnegan.com	
Laura P. Masurovsky	
laura.masurovsky@finnegan.com	
Aaron G. Clay	
aaron.clay@finnegan.com	
John E. Nappi	
john.nappi@finnegan.com	
Eric J. Fues	
eric.fues@finnegan.com	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP	
901 New York Ave., NW	
Washington, DC 20001	

Dated: January 3, 2020

/s/ William J. O'Brien